Try our beta test site

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Sarcoma Alliance for Research through Collaboration
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration Identifier:
First received: January 21, 2014
Last updated: January 19, 2017
Last verified: January 2017
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide in patients with pre-treated incurable Ewing sarcoma.

Condition Intervention Phase
Ewing Sarcoma
Drug: niraparib
Drug: Temozolomide
Drug: Irinotecan
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma

Resource links provided by NLM:

Further study details as provided by Sarcoma Alliance for Research through Collaboration:

Primary Outcome Measures:
  • Dose-limiting toxicity and maximum tolerated dose [ Time Frame: Approximately 24 months ]
    Dose limiting toxicity describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The maximum tolerated dose is the highest dose of a drug or treatment that does not cause unacceptable side effects.

Secondary Outcome Measures:
  • Tumor response rate of patients treated with niraparib and temozolomide. [ Time Frame: Approximately 24 months ]
    The percentage of patients whose tumor shrinks or disappears after treatment with niraparib and temozolomide.

  • Progression-free survival at 4 and 6 months of patients treated with niraparib and temozolomide [ Time Frame: Month 4 and 6 ]

Estimated Enrollment: 50
Study Start Date: May 2014
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: niraparib and temozolomide
Niraparib and temozolomide will be taken together
Drug: niraparib Drug: Temozolomide
Experimental: niraparib and irinotecan
Niraparib will be taken orally and Irinotecan intravenously
Drug: niraparib Drug: Irinotecan


Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed Ewing sarcoma
  • Evidence of Ewing sarcoma translocation by FISH or RT-PCR.
  • Must be willing to undergo tumor biopsy at study entry for biologic correlates.
  • If patient > 18 years, must be willing to undergo on-treatment tumor biopsy unless medically contra-indicated
  • Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.
  • Age ≥ 13 years.
  • Life expectancy of ≥ 3 months.
  • ECOG performance status 0-2.
  • Measurable disease on CT or MRI by RECIST 1.1.
  • Adequate organ function
  • Patients must have received as a minimum a first line chemotherapy regimen consisting of at least 2 of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide.
  • Time elapsed from previous therapy must be ≥ 3 weeks for systemic therapy, ≥ 2 weeks for radiation therapy or major surgery.
  • Patients who have undergone autologous hematopoietic stem cell transplantation are eligible once they have recovered from all toxicities from therapy
  • Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible 6 months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least 30 days.
  • Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are ≥ 6 weeks from completion of brain irradiation.
  • Patients or their legal representative (if the patient is < 18 years old) must be able to read, understand and provide written informed consent to participate in the trial.
  • Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.

Exclusion Criteria:

  • Clinically significant unrelated illness which would, in the judgment of the treating physician, compromise the patient's ability to tolerate the investigational agent or be likely to interfere with the study procedures or results.
  • Patients with baseline QTc > 480 msec.
  • Inability to swallow capsules.
  • Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
  • Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2
  • Concomitant use of any other investigational or anticancer agent(s).
  • Pregnant patients or patients who are breast feeding. Subjects capable of pregnancy (post menarche and not post-menopausal, defined as over 12 months since final menstrual period) must have a negative pregnancy test within 7 days prior to first dose.
  • Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer.
  • Active central nervous system disease.
  • Known history of MDS.
  • Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02044120

Contact: SARC Office 734-930-7600

United States, California
Children's Hospital of Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Leo Mascerenhas, MD   
United States, Maryland
National Cancer Institute Recruiting
Bethesda, Maryland, United States, 20892
Contact: Brigitte Widemann, MD   
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Rashmi Chugh, MD   
United States, Washington
Seattle's Children Cancer Center Recruiting
Seattle, Washington, United States, 98101
Contact: Doug Hawkins, MD   
United Kingdom
University College London Hospital Recruiting
London, United Kingdom, W1T 7HA
Contact: Sandra Strauss   
Sponsors and Collaborators
Sarcoma Alliance for Research through Collaboration
  More Information

Responsible Party: Sarcoma Alliance for Research through Collaboration Identifier: NCT02044120     History of Changes
Other Study ID Numbers: ESP1/SARC025
Study First Received: January 21, 2014
Last Updated: January 19, 2017

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Poly(ADP-ribose) Polymerase Inhibitors
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents processed this record on March 24, 2017